Background: Identification of patients with Hodgkin lymphoma (HL) at risk of treatment failure remains an important unsolved question. Several prognostic models have been proposed to define risk-adapted therapeutic strategies, avoiding overtreatment and identifying in whom standard treatment is not sufficient. Aims: To test validated prognostic factors and identify other predictors of survival in a cohort of patients with classical HL (cHL) in a tertiary health institution. Methods: Retrospective analysis of patients with cHL treated between 1990 and 2015. Univariate analysis was performed and significant predictors at the level of 0.05 were used to adjust a multivariate Cox regression model. Results: We included 355 cHL patients, mainly males (55.2%) with a median age at diagnosis of 29 years (12-80). The most prevalent histological subtype was nodular sclerosis (78.3%). Ann Arbor stage III/IV was observed in 41.1% (n=146) patients, B symptoms in 54.6% (n=194) and bulky disease in 22.8% (n=81). According to GHSG criteria, 50.1% (n=178) had advanced disease of which 49.4% (n=88) had an IPS≥3. Among the 344 patients treated, ABVD was performed in 210 (59.2%); MOPP/ABVD in 78 (21.9%); MOPP/MOPP like in 30 (8.5%); BEACOPP in 25 (7.0%); other regimens in 17 patients (4.8%) and radiotherapy alone in 11 (3.1%). Overall response rate was 83.9% (77.2% of complete responses). With a median follow-up of 100.1 months (0.3-316.0), overall survival (OS) at 5, 10 and 20 years was 84.3%, 78.1% and 67.8% and progression free survival (PFS) was 71.6%, 67.3% and 57.9%, respectively. We analyze the prognostic significance of several factors accepted previously with regard to survival. On multivariate regression analysis only 3 factors were associated with impact on OS: age (HR 1.04; 95%CI 1.02-1.06, p<0.001); hemoglobin level (HR 0.78; 95%CI 0.66-0.93, p=0.005) and LDH>2xULN (HR 2.13; 95%CI 1.06-4.28, p=0.034). Four factors were predictors of PFS: age (HR 1.02; 95%CI 1.01-1.04, p<0.004); lymphocyte count (HR 0.60; 95%CI 0.39-0.92, p=0.02), LDH>2xULN (HR 2.55; 95%CI 1.31-4.97, p=0.006) and Ann Arbor stage III/VI (HR 2.40; 95%CI 1.18-4.86, p=0.015). Conclusion: This data provides evidence for age, hemoglobin and LDH as independent predictors of OS and age, lymphocyte count, LDH and Ann Arbor stage as predictors of PFS in patients with cHL. Further work in larger groups is warranted to create an accurate predictive model for adequate stratification of newly diagnosed patients.